Lee Crews, Ph.D., practices in the area of intellectual property law. Dr. Crews assists clients in the life sciences and medical devices fields with securing patent rights in the United States and abroad. She also represents clients in those industries in licensing and transactional work, and has significant experience in resolving inventorship disputes. Dr. Crews' clients concentrate on antibody engineering, diagnostic agents, gene therapies, high-throughput screening assays, RNAi and microRNAs, implantable devices, pharmaceuticals, vaccines, stem cells, and transgenic plants and animals. Her clients include universities, pharmaceutical companies and start-up and mid-market biotech companies.
Previously, Dr. Crews was a postdoctoral Fellow at Tufts University School of Medicine, where she studied neurotransmitter regulation. At the Ludwig Institute for Cancer Research in London, she used cellular and molecular techniques to investigate cellular patterning and differentiation. She has co-authored articles in the Journal of Neuroscience and the Proceedings of the Royal Society.
Dr. Crews is a 2000 graduate of Boston University School of Law and a graduate of Emory University School of Medicine (Ph.D.) and the University of Central Florida (B.S.).
Areas of Practice
· Intellectual Property
· Medical Devices
· Life Sciences
Professional Activities
· Law360 Editorial Advisory Board
- Intellectual Property Section, 2010
Experience
· Duane Morris LLP
- Partner, 2009-present
· Fish & Richardson P.C.
- Principal, 2005-2009
- Associate, 2000-2004
- Technology Specialist, 1995-2000
· Tufts University School of Medicine
- Postdoctoral Fellow, 1992-1995
· The Ludwig Institute for Cancer Research
- Postdoctoral Fellow, 1989-1992
Selected Publications
· Co-author, "FDA Issues Draft Guidance Documents to Implement the Biologics Price Competition and Innovation Act of 2009," Duane Morris Alert, February 13, 2012
· Co-author, "District Court Invalidates Claims to Isolated DNA Molecules and Methods of Their Use; Finds Subject Matter Ineligible for Patent Protection," Duane Morris Alert, March 31, 2010